Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 April 2021Website:
http://www.ginkgobioworks.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 10 min agoDividend
Analysts recommendations
Institutional Ownership
DNA Latest News
Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower.
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its operations, with plans to lay off 200 employees, or roughly 40% of its workforce. The company also said it will discontinue development of its therapeutic programs.
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.
Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030.
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2024-DNA3 Notes, Freddie Mac STACR REMIC Trust 2024-DNA3 (STACR 2024-DNA3), a credit risk sharing transaction with a total note offering of $642,500,000. STACR 2024-DNA3 features loans with loan-to-value (LTV) ratios greater than 60%, but less than or equal to 80%. The Offered Notes represent obligations of the STACR 2024-DNA3 Trust in a credit-linked note stru.
What type of business is Ginkgo Bioworks Holdings?
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
What sector is Ginkgo Bioworks Holdings in?
Ginkgo Bioworks Holdings is in the Healthcare sector
What industry is Ginkgo Bioworks Holdings in?
Ginkgo Bioworks Holdings is in the Biotechnology industry
What country is Ginkgo Bioworks Holdings from?
Ginkgo Bioworks Holdings is headquartered in United States
When did Ginkgo Bioworks Holdings go public?
Ginkgo Bioworks Holdings initial public offering (IPO) was on 19 April 2021
What is Ginkgo Bioworks Holdings website?
https://www.ginkgobioworks.com
Is Ginkgo Bioworks Holdings in the S&P 500?
No, Ginkgo Bioworks Holdings is not included in the S&P 500 index
Is Ginkgo Bioworks Holdings in the NASDAQ 100?
No, Ginkgo Bioworks Holdings is not included in the NASDAQ 100 index
Is Ginkgo Bioworks Holdings in the Dow Jones?
No, Ginkgo Bioworks Holdings is not included in the Dow Jones index
When was Ginkgo Bioworks Holdings the previous earnings report?
No data
When does Ginkgo Bioworks Holdings earnings report?
The next expected earnings date for Ginkgo Bioworks Holdings is 28 February 2025